Trials / Conditions / Borderline Resectable Pancreatic Cancer

Borderline Resectable Pancreatic Cancer

15 registered clinical trials studyying Borderline Resectable Pancreatic Cancer — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP) NCT07477418	University of Vermont	Phase 1 / Phase 2
Not Yet Recruiting	Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally A NCT07325214	IMGT Co., Ltd.	N/A
Not Yet Recruiting	EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases NCT07448376	Huazhong University of Science and Technology	—
Recruiting	A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Ca NCT06944587	Oslo University Hospital	—
Recruiting	DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer NCT06173310	Ohio State University	N/A
Recruiting	Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Re NCT06387810	Peking Union Medical College Hospital	Phase 2
Unknown	NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study NCT06345300	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 2
Unknown	AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer NCT04617821	Fudan University	Phase 3
Terminated	Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer NCT04698915	Galera Therapeutics, Inc.	Phase 2
Unknown	Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC NCT04855331	Fudan University	N/A
Suspended	IORT on Borderline Resectable Pancreatic Cancer NCT04090463	Universita di Verona	Phase 2
Unknown	Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer NCT03850769	Peking Union Medical College Hospital	Phase 2
Unknown	Divestment for Artery-involved Pancreatic Cancer NCT03443921	The First Affiliated Hospital with Nanjing Medical University	N/A
Unknown	Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer NCT02717091	Nagoya University	Phase 2
Terminated	Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiat NCT02241551	Nathan Bahary, MD	Phase 2